A FIRST-IN-HUMAN TRIAL OF HSTC810 (ANTI-BTN1A1 AB), A NOVEL IMMUNE CHECKPOINT WITH A MUTUALLY EXCLUSIVE EXPRESSION WITH PD-1/PD-L1, IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS

被引：1
|
作者：
Lee, Soohyeon [1 ]
Shin, Sangjoon [2 ]
Howie, Lynn [3 ]
Jung, Hyunjin [4 ]
Yoo, Steven [3 ,4 ]
Hong, David [5 ]
机构：
[1] Korea Univ, Anam Hosp, Seoul, South Korea
[2] Yonsei Canc Ctr, Seoul, South Korea
[3] STCube Pharmaceut Inc, Gaithersburg, MD USA
[4] STCube Inc, Seoul, South Korea
[5] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
740
引用
收藏
页码：A773 / A773
页数：1
相关论文
共 50 条
  • [1] Development of a diagnostic antibody for anti-BTN1A1 therapy, a novel immune checkpoint inhibitor mutually exclusive of PD-L1/PD-1
    Yoo, Stephen S.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1
    Kim, Young-Seung
    Lee, Seung-Hoon
    Park, Andrew H.
    Wu, Chunai
    Hong, Bong-Ki
    Jung, Hyunjin
    Lin, Steven H.
    Yoo, Stephen S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [3] A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors
    Lee, Soohyeon
    Shin, Sangjoon
    LoRusso, Patricia
    Rolfo, Christian Diego
    Jung, Hyunjin
    Yoo, Stephen Sunghan
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
  • [5] Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Shinyashiki, Yu
    Ito, Tomohiko
    Kakinoki, Ryosuke
    Akagi, Masao
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2023, 67 (02):
  • [6] BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis.
    Chung, Ezra M.
    Bong, Yong-Sik
    Kim, Young-Seung
    Park, Andrew
    You, Young-Ok
    Sharma, Amrish
    Lin, Steven H.
    Lee, Young-Joon
    Jung, Hyunjin
    Yoo, Stephen S.
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors
    Carneiro, Benedito A.
    Safran, Howard
    Beck, J. Thaddeus Thaddeus
    Hamid, Omid
    Spira, Alexander I.
    Savvides, Panos
    Gutierrez, Martin
    Zhao, Yujie
    Abbruzzese, James L.
    Ward, Jeffrey P.
    Weroha, Saravut John
    Harris, Loleta D.
    Kent, Sean
    Pierceall, William
    Skoura, Athanasia
    Zheng, Jenny
    Kern, Kenneth Alan
    Thomas, Jacob Stephen
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [9] PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
    Tang, Quanying
    Zhao, Shikang
    Zhou, Ning
    He, Jinling
    Zu, Lingling
    Liu, Tingwen
    Song, Zuoqing
    Chen, Jun
    Peng, Ling
    Xu, Song
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 62 (04)
  • [10] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Baquerizo, Angeles
    Vavinskaya, Vera
    Rojas, Angela
    Mhoyan, Anna
    Romero-Gomez, Manuel
    Sher, Linda
    Madani, Bahar
    Fisher, Jonathan
    Schaffer, Randolph
    Frenette, Catherine T.
    Marsh, Christopher
    HEPATOLOGY, 2019, 70 : 206A - 206A
12345